Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

CompletedOBSERVATIONAL
Enrollment

963

Participants

Timeline

Start Date

July 19, 2011

Primary Completion Date

December 26, 2012

Study Completion Date

November 27, 2013

Conditions
Inoperable or Recurrent Breast Cancer
Interventions
DRUG

Eribulin Mesylate

The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.

Trial Locations (223)

Unknown

Anjo

Inazawa

Kariya

Komaki

Nagakute

Nagoya

Okazaki

Seto

Tahara

Toyohashi

Daisen

Yokote

Goshogawara

Hirosaki

Kuroishi

Misawa

Mutsu

Asahi

Funabashi

Ichihara

Ichikawa

Kashiwa

Kimitsu

Matsudo

Sakura

Matsuyama

Niihama

Iizuka

Kasuga

Kitakyushu

Kurume

Omuta

Yame

Yanagawa

Minamisoma

Nihommatsu

Ena

Hashima

Minokamo

Ōgaki

Sekimachi

Tajimi

Takayama

Maebashi

Ōta

Shibukawa

Takasaki

Aki

Fukuyama

Hatsukaichi

Higashihiroshima

Kure

Mihara

Onomichi

Abashiri

Asahikawa

Date

Eniwa

Hakodate

Kitahiroshima

Kitami

Kushiro

Muroran

Obihiro

Sapporo

Shibetsu

Akashi

Amagasaki

Himeji

Kobe

Nishinomiya

Toyooka

Higashiibaraki

Inashiki

Kamisu

Kasama

Koga

Moriya

Tsukuba

Ushiku

Kahoku

Kanazawa

Komatsu

Nomi

Takamatsu

Akune

Chigasaki

Ebina

Isehara

Kamakura

Kawasaki

Odawara

Sagamihara

Yokohama

Yokosuka

Arao

Tamana

Kōtari

Ise

Matsusaka

Suzuka

Tsu

Yokkaichi

Murata

Ōsaki

Sendai

Iida

Komagane

Matsumoto

Saku

Suwa

Shimabara

Ikoma

Kashihara

Yamatotakada

Minamiuonuma

Kurashiki

Maniwa

Tamano

Wake

Naha

Nakagami

Shimajiri

Tomigusuku

Urasoe

Higashiosaka

Hirakata

Ibaraki

Izumiōtsu

Katano

Neyagawa

Sayama

Takatsuki

Yao

Karatsu

Fujimino

Fukaya

Hidaka

Hiki

Kawaguchi

Kumagaya

Toda

Tokorozawa

Kusatsu

Ōtsu

Rittō

Izumo

Matsue

Fujieda

Fujinomiya

Gotemba

Hamamatsu

Izunokuni

Numazu

Shimada

Sunto

Ashikaga

Oyama

Adachi City

Akishima

Bunkyo

Chiyoda City

Chūō

Fuchū

Fussa

Hachiōji

Hino

Katsushika-ku

Kita-ku

Koto

Machida

Meguro City

Minato

Mitaka

Nerima City

Ōta-ku

Setagaya City

Shibuya City

Shinagawa

Shinjuku

tabashi City

Tachikawa

Taitō City

Tama

Kurayoshi

Yonago

Nakaniikawa

Namerikawa

Oyabe

Takaoka

Tsuruoka

Hagi

Iwakuni

Nagato

Shimonoseki

Chūō

Kofu

Minamikoma

Aomori

Chiba

Fukui

Fukuoka

Fukushima

Gifu

Hiroshima

Kagoshima

Kochi

Kumamoto

Kyoto

Miyazaki

Nagano

Nagasaki

Niigata

Okayama

Okinawa

Osaka

Ōita

Saga

Saitama

Shizuoka

Tokushima

Tottori

Toyama

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT01463891 - Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) | Biotech Hunter | Biotech Hunter